JP2016529312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529312A5 JP2016529312A5 JP2016540387A JP2016540387A JP2016529312A5 JP 2016529312 A5 JP2016529312 A5 JP 2016529312A5 JP 2016540387 A JP2016540387 A JP 2016540387A JP 2016540387 A JP2016540387 A JP 2016540387A JP 2016529312 A5 JP2016529312 A5 JP 2016529312A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- carbocyclyl
- heterocyclyl
- alkynyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC(*(C)C)=C*=C(*)[*@]1*=CC(C(C=**2C(C(CC)=C3C)=O)=C2*3=C)=C1 Chemical compound CCC(*(C)C)=C*=C(*)[*@]1*=CC(C(C=**2C(C(CC)=C3C)=O)=C2*3=C)=C1 0.000 description 4
- CSLJXILIWIMLTL-UHFFFAOYSA-N CC(C)c1c[n](-c(nc2)ncc2N(C)C)nc1 Chemical compound CC(C)c1c[n](-c(nc2)ncc2N(C)C)nc1 CSLJXILIWIMLTL-UHFFFAOYSA-N 0.000 description 1
- ZAZCIHKBUVQXKV-UHFFFAOYSA-N CC(Nc([n](C1=O)nc2)c2-c2c[n](-c3ccccn3)nc2)=C1Cl Chemical compound CC(Nc([n](C1=O)nc2)c2-c2c[n](-c3ccccn3)nc2)=C1Cl ZAZCIHKBUVQXKV-UHFFFAOYSA-N 0.000 description 1
- XCJHHYWFOXAYBC-UHFFFAOYSA-N CC(c1c[n](-c2ccncn2)nc1)=C Chemical compound CC(c1c[n](-c2ccncn2)nc1)=C XCJHHYWFOXAYBC-UHFFFAOYSA-N 0.000 description 1
- VVAMRKQTTRRZBC-LSDHQDQOSA-N CC/C(/[n]1cnc(-c2ccccn2)c1)=C(/NC(c1ccccc1)=C(CC)C1=O)\N1N Chemical compound CC/C(/[n]1cnc(-c2ccccn2)c1)=C(/NC(c1ccccc1)=C(CC)C1=O)\N1N VVAMRKQTTRRZBC-LSDHQDQOSA-N 0.000 description 1
- LPLZTGZNKNRTLL-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-[n]1cnc(-c2ccccn2)c1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-[n]1cnc(-c2ccccn2)c1 LPLZTGZNKNRTLL-UHFFFAOYSA-N 0.000 description 1
- UTTNHAMRKOCBMO-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-[n]1cnc(-c2cccnc2)c1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-[n]1cnc(-c2cccnc2)c1 UTTNHAMRKOCBMO-UHFFFAOYSA-N 0.000 description 1
- WWYNJDQPWNRJLC-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2cc(N(C)C)ccn2)nc1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2cc(N(C)C)ccn2)nc1 WWYNJDQPWNRJLC-UHFFFAOYSA-N 0.000 description 1
- PQCIOURXCUVAEZ-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2nccc(Cl)c2)nc1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2nccc(Cl)c2)nc1 PQCIOURXCUVAEZ-UHFFFAOYSA-N 0.000 description 1
- RTWAURZQZXFUNZ-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2nccc(OC)c2)nc1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2nccc(OC)c2)nc1 RTWAURZQZXFUNZ-UHFFFAOYSA-N 0.000 description 1
- RMLRQNYPXZAZLZ-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2ncccn2)nc1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2ncccn2)nc1 RMLRQNYPXZAZLZ-UHFFFAOYSA-N 0.000 description 1
- ANRQHYNHPUYMMB-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1cnc(-c2ccccn2)[nH]1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1cnc(-c2ccccn2)[nH]1 ANRQHYNHPUYMMB-UHFFFAOYSA-N 0.000 description 1
- JPEUQZVNSKXPHA-UHFFFAOYSA-N CNc1c[n](-c2nc(N(C)C)ccn2)nc1 Chemical compound CNc1c[n](-c2nc(N(C)C)ccn2)nc1 JPEUQZVNSKXPHA-UHFFFAOYSA-N 0.000 description 1
- ZTDDWLMWLULANI-UHFFFAOYSA-N Cc1ccnc(-[n]2ncc(N)c2)n1 Chemical compound Cc1ccnc(-[n]2ncc(N)c2)n1 ZTDDWLMWLULANI-UHFFFAOYSA-N 0.000 description 1
- XHRMXJNKNQKYRQ-UHFFFAOYSA-N O=C1[n]2ncc(-c3c[n](-c4ccccn4)nc3)c2NC2=C1CCC2 Chemical compound O=C1[n]2ncc(-c3c[n](-c4ccccn4)nc3)c2NC2=C1CCC2 XHRMXJNKNQKYRQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361874310P | 2013-09-05 | 2013-09-05 | |
| US61/874,310 | 2013-09-05 | ||
| PCT/US2014/054114 WO2015035062A1 (en) | 2013-09-05 | 2014-09-04 | Antiproliferative compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016529312A JP2016529312A (ja) | 2016-09-23 |
| JP2016529312A5 true JP2016529312A5 (cg-RX-API-DMAC10.html) | 2017-09-07 |
| JP6336598B2 JP6336598B2 (ja) | 2018-06-06 |
Family
ID=51541384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540387A Expired - Fee Related JP6336598B2 (ja) | 2013-09-05 | 2014-09-04 | 抗増殖性化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9505767B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3041474B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6336598B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20160049003A (cg-RX-API-DMAC10.html) |
| CN (1) | CN105611933B (cg-RX-API-DMAC10.html) |
| CA (1) | CA2922925A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2016002794A (cg-RX-API-DMAC10.html) |
| RU (1) | RU2016112568A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2015035062A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102160320B1 (ko) | 2012-10-02 | 2020-09-28 | 에피테라퓨틱스 에이피에스 | 히스톤 탈메틸효소의 저해제 |
| ES2670864T3 (es) | 2013-02-27 | 2018-06-01 | Gilead Sciences, Inc. | Inhibidores de histonas desmetilasas |
| MX2015011898A (es) | 2013-03-13 | 2016-05-05 | Genentech Inc | Compuestos de pirazolo y usos de los mismos. |
| TW201625536A (zh) | 2014-08-27 | 2016-07-16 | 艾比療法公司 | 抑制組蛋白去甲基酶之化合物及方法 |
| CN107001358A (zh) | 2014-10-29 | 2017-08-01 | 东亚St株式会社 | 调节组蛋白赖氨酸脱甲基酶(kdm)催化活性的新型吡啶并嘧啶酮化合物 |
| US20180127748A1 (en) * | 2015-05-15 | 2018-05-10 | The General Hospital Corporation | Methods relating to the prevention and treatment of drug resistance |
| UA125852C2 (uk) | 2016-08-31 | 2022-06-22 | Ле Лаборатуар Сервьє | Інгібітори клітинних метаболічних процесів |
| US20200048259A1 (en) * | 2016-10-12 | 2020-02-13 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| EP3525785B1 (en) * | 2016-10-12 | 2025-08-27 | Merck Sharp & Dohme LLC | Kdm5 inhibitors |
| WO2018160356A1 (en) | 2017-02-28 | 2018-09-07 | University Of Massachusetts | Genetic and pharmacological transcriptional upregulation of the repressed fxn gene as a therapeutic strategy for friedreich ataxia |
| CN108947985A (zh) * | 2017-05-22 | 2018-12-07 | 苏州偶领生物医药有限公司 | 用作自噬调节剂的化合物及其制备方法和用途 |
| EP3672597A4 (en) * | 2017-08-21 | 2021-09-22 | Navigen, Inc. | ARF6 INHIBITORS AND RELATED PROCEDURES |
| CN111212839A (zh) * | 2017-09-15 | 2020-05-29 | 艾杜罗生物科技公司 | 吡唑并嘧啶酮化合物及其用途 |
| US20220242872A1 (en) * | 2019-06-24 | 2022-08-04 | Dana-Farber Cancer Institute, Inc. | E3 ligase binders and uses thereof |
| JP2022541954A (ja) * | 2019-07-17 | 2022-09-28 | 小野薬品工業株式会社 | Ｋｄｍ５阻害活性を有する化合物およびその医薬用途 |
| CN114728167B (zh) | 2019-11-25 | 2024-03-19 | 安进公司 | 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法 |
| WO2023134692A1 (zh) * | 2022-01-13 | 2023-07-20 | 浙江同源康医药股份有限公司 | 多环类化合物及其用途 |
| EP4511116A1 (en) | 2022-04-22 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CN120187416A (zh) | 2022-11-11 | 2025-06-20 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| WO2025194015A1 (en) * | 2024-03-15 | 2025-09-18 | Dem Biopharma, Inc. | Heteroaryl modulators of gpr84 and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| JP2975679B2 (ja) | 1989-09-08 | 1999-11-10 | ザ・ジョーンズ・ホプキンス・ユニバーシティ | ヒト神経膠腫のｅｇｆ受容体遺伝子の構造変化 |
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| EP0772609B1 (en) | 1994-07-21 | 1999-02-24 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| EP2295415A1 (en) | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| CZ1598A3 (cs) | 1995-07-06 | 1998-04-15 | Novartis Ag | Pyrrolopyrimidiny a způsoby jejich přípravy |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GEP20012442B (en) | 1996-04-12 | 2001-05-25 | Warner Lambert Co | Irreversible Inhibitors of Tyrosine Kinases |
| EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| AU1308799A (en) | 1997-11-06 | 1999-05-31 | American Cyanamid Company | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| JP4100865B2 (ja) * | 1999-12-13 | 2008-06-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 三環式縮合異項環化合物、その製造法およびその医薬 |
| TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
| EP1511751B1 (en) | 2002-06-04 | 2008-03-19 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents |
| US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| EP2069351B1 (en) * | 2006-06-20 | 2015-10-28 | AbbVie Inc. | Pyrazoloquinazolinones as parp inhibitors |
| WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| CN101906105B (zh) * | 2009-06-08 | 2013-01-16 | 河北医科大学 | 吡唑并[1，5-a]嘧啶酮衍生物及其药物组合物以及其用途 |
| US10953012B2 (en) * | 2011-04-26 | 2021-03-23 | Bioenergenix Llc | Heterocyclic compounds for the inhibition of pask |
| WO2014066795A1 (en) * | 2012-10-25 | 2014-05-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| DK2961741T3 (en) * | 2013-03-01 | 2017-07-03 | Fund Para La Investig Medica Aplicada | Novel compounds as dual inhibitors of phosphodiesterases and histone deacetylases |
| MX2015011898A (es) | 2013-03-13 | 2016-05-05 | Genentech Inc | Compuestos de pirazolo y usos de los mismos. |
-
2014
- 2014-09-04 WO PCT/US2014/054114 patent/WO2015035062A1/en not_active Ceased
- 2014-09-04 KR KR1020167008823A patent/KR20160049003A/ko not_active Withdrawn
- 2014-09-04 CA CA2922925A patent/CA2922925A1/en not_active Abandoned
- 2014-09-04 RU RU2016112568A patent/RU2016112568A/ru not_active Application Discontinuation
- 2014-09-04 MX MX2016002794A patent/MX2016002794A/es unknown
- 2014-09-04 CN CN201480055129.0A patent/CN105611933B/zh active Active
- 2014-09-04 US US14/477,566 patent/US9505767B2/en active Active
- 2014-09-04 JP JP2016540387A patent/JP6336598B2/ja not_active Expired - Fee Related
- 2014-09-04 EP EP14766355.3A patent/EP3041474B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529312A5 (cg-RX-API-DMAC10.html) | ||
| RU2016112568A (ru) | Антипролиферативные соединения | |
| JP2017530984A5 (cg-RX-API-DMAC10.html) | ||
| JP2018505169A5 (cg-RX-API-DMAC10.html) | ||
| Manara et al. | NVP-BEZ235 as a new therapeutic option for sarcomas | |
| ES2694513T3 (es) | Derivado de quinolina | |
| IL275333B2 (en) | Inhibitors of fibroblast activation protein | |
| JP2018510851A5 (cg-RX-API-DMAC10.html) | ||
| TWI690525B (zh) | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 | |
| JP2017528475A5 (cg-RX-API-DMAC10.html) | ||
| JP2016525075A5 (cg-RX-API-DMAC10.html) | ||
| RU2018103944A (ru) | Производные этинила как модуляторы метаботропного рецептора глутамата | |
| JP2018520195A5 (cg-RX-API-DMAC10.html) | ||
| JP2010522194A5 (cg-RX-API-DMAC10.html) | ||
| EA201690531A1 (ru) | ПРОИЗВОДНЫЕ 1-(5-ТРЕТ-БУТИЛ-2-АРИЛПИРАЗОЛ-3-ИЛ)-3-[2-ФТОР-4-[(3-ОКСО-4H-ПИРИДО[2,3-b]ПИРАЗИН-8-ИЛ)ОКСИ]ФЕНИЛ]МОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ RAF ДЛЯ ЛЕЧЕНИЯ РАКА | |
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| JP2016504365A5 (cg-RX-API-DMAC10.html) | ||
| RU2008136188A (ru) | Противораковая фармацевтическая композиция | |
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| RU2016130932A (ru) | Производные хинолона как ингибиторы рецептора фактора роста фибробластов | |
| RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
| RU2015116749A (ru) | Антагонисты mglu2/3 для лечения аутических расстройств | |
| RU2013147823A (ru) | (альфа-замещенные аралкиламино-и гетероарилалкиламино)пиримидинил-и 1, 3, 5-триазинилбензимидазолы, их фармацевтические композиции и их применение в лечении пролиферативных заболеваний | |
| KR20150081344A (ko) | 조합 요법 | |
| EP3053578B1 (en) | Combination cancer therapy using azabicyclo compound |